MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease
In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows t...
Saved in:
Published in | Clinical and translational gastroenterology Vol. 11; no. 3; p. e00134 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
01.03.2020
Wolters Kluwer |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis.
The miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems.
When compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0-1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001).
MiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. |
---|---|
AbstractList | In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis.
The miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems.
When compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0-1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001).
MiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. OBJECTIVESIn patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis. METHODSThe miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems. RESULTSWhen compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0-1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001). DISCUSSIONMiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. OBJECTIVES:In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis.METHODS:The miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems.RESULTS:When compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r2 = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0–1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001).DISCUSSION:MiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis. OBJECTIVES: In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis. METHODS: The miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems. RESULTS: When compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r 2 = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0–1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001). DISCUSSION: MiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. |
Author | Nowacki, Tobias Brückner, Markus Lenze, Frank Cordes, Friederike Schmidt, M Alexander Lenz, Philipp Tepasse, Phil Cichon, Christoph Bettenworth, Dominik Demmig, Claudia Bokemeyer, Arne Schmidt, Hartmut H |
Author_xml | – sequence: 1 givenname: Friederike surname: Cordes fullname: Cordes, Friederike organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 2 givenname: Claudia surname: Demmig fullname: Demmig, Claudia organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 3 givenname: Arne surname: Bokemeyer fullname: Bokemeyer, Arne organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 4 givenname: Markus surname: Brückner fullname: Brückner, Markus organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 5 givenname: Frank surname: Lenze fullname: Lenze, Frank organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 6 givenname: Philipp surname: Lenz fullname: Lenz, Philipp organization: Institute of Palliative Care, University Hospital Münster, Münster, Germany – sequence: 7 givenname: Tobias surname: Nowacki fullname: Nowacki, Tobias organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 8 givenname: Phil surname: Tepasse fullname: Tepasse, Phil organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 9 givenname: Hartmut H surname: Schmidt fullname: Schmidt, Hartmut H organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany – sequence: 10 givenname: M Alexander surname: Schmidt fullname: Schmidt, M Alexander organization: Institute of Infectiology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany – sequence: 11 givenname: Christoph surname: Cichon fullname: Cichon, Christoph organization: Institute of Infectiology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany – sequence: 12 givenname: Dominik surname: Bettenworth fullname: Bettenworth, Dominik organization: Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32352717$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkV1PHCEYhUlj0_Vjf0KbSbzxZizwwjBzY7La-pH4FdNGr0oYFhQzAzqwmv33Yt1utssNJDzn5D3v2UIbPniD0FeC9wkD3HzX6X4frx4C7BPapITzEmp2t7HyHqFxjI_vEMO0bpovaAQUOBVEbKI_F04P4eZyUgLFqrgI3qUwxOLMJxOT86orfrhoVDTFRCf34tK8cL64VskZn2Jx69JDhm2n-l5l5bw4DK9mKdpBn63qohkv7m30-_jnr6PT8vzq5Oxocl5qBk0qG1pVFhgzwlRY2Ao4tpbQ1nLCCdXQgK2nVkGrpi0VWrdcc8iYmNY5EXDYRgcfvk-ztjdTnWcbVCefBterYS6DcvL_H-8e5H14kYIwjgGywd7CYAjPsxxd9i5q03XKmzCLkkIjKi44oxndXUMfw2zIm8oU4w2jNcdVpvgHldcb42DschiC5d8SZS5RrpeYdd9WkyxV_yqDN0GomcE |
CitedBy_id | crossref_primary_10_3389_fphar_2022_941656 crossref_primary_10_1053_j_gastro_2023_05_037 crossref_primary_10_3748_wjg_v30_i16_2184 crossref_primary_10_1093_ibd_izac250 crossref_primary_10_3390_cells10123358 crossref_primary_10_3390_ijms24087176 crossref_primary_10_3390_ijms23158751 crossref_primary_10_3390_ijms23147991 crossref_primary_10_1016_j_cgh_2021_05_054 crossref_primary_10_1053_j_gastro_2021_09_076 crossref_primary_10_1093_ecco_jcc_jjab223 crossref_primary_10_3390_medicina60020305 crossref_primary_10_4251_wjgo_v13_i9_995 crossref_primary_10_1080_08916934_2023_2220988 crossref_primary_10_3389_fped_2022_1053965 crossref_primary_10_1186_s13018_023_03984_2 |
Cites_doi | 10.1093/jnci/dju492 10.1007/s00464-007-9251-7 10.1007/s11095-017-2134-2 10.3109/00365521.2014.987809 10.1038/ajg.2009.545 10.1002/ibd.22917 10.1097/01.MIB.0000173271.18319.53 10.1097/MIB.0000000000000917 10.1186/s13046-015-0198-6 10.1089/dna.2016.3426 10.1038/ncpgasthep0528 10.1136/gutjnl-2014-307891 10.1056/NEJMoa050516 10.1093/ecco-jcc/jju003 10.1371/journal.pone.0064795 10.1007/s11894-015-0449-x 10.1002/ibd.22861 10.1136/gut.2007.146357 10.1016/j.cgh.2007.09.002 10.1053/j.gastro.2009.09.056 10.1016/S0016-5107(04)01878-4 10.1016/j.cgh.2016.01.015 10.1016/j.cgh.2015.06.001 10.1634/theoncologist.2011-0466 10.1186/s12885-015-1238-5 10.1177/2050640618774416 10.1016/j.gie.2008.09.008 10.1093/ecco-jcc/jjy114 10.1155/2018/2474529 10.1111/jgh.13611 10.1053/j.gastro.2011.06.054 10.1016/j.cgh.2015.05.038 10.1016/j.cgh.2014.01.029 10.1053/j.gastro.2006.12.038 10.1053/j.gastro.2007.05.051 10.1016/S0140-6736(17)32641-7 10.1038/ajg.2015.233 10.3748/wjg.v23.i46.8235 10.3109/00365521.2015.1117650 10.1373/clinchem.2010.157198 10.1111/j.1651-2227.2010.01843.x 10.1136/flgastro-2016-100762 10.1016/j.crohns.2014.02.014 10.1258/acb.2012.011272 10.1016/j.amjmed.2008.06.034 10.1111/j.1365-2036.2008.03835.x 10.1111/j.1572-0241.2007.01126.x 10.1053/j.gastro.2003.11.010 10.1038/bjc.2012.546 10.1177/2050640613518201 10.1038/bjc.2013.819 10.1016/S0016-5085(76)80163-1 10.5009/gnl17445 10.1016/j.biocel.2011.11.006 10.4161/rna.18827 10.1007/s10620-016-4104-7 10.1056/NEJM198712243172603 10.1097/MCG.0b013e3181cadbc0 10.1097/MIB.0000000000000057 10.1002/ibd.21925 10.3389/fgene.2019.00626 10.1016/j.crohns.2013.09.016 10.3109/00365521.2012.660542 10.1136/gut.2005.069476 10.1111/j.1365-2362.1982.tb02244.x 10.1038/ajg.2016.59 10.1038/nrgastro.2013.233 10.1111/1469-0691.12418 10.1002/ibd.20275 10.1016/S0140-6736(15)00068-9 10.1093/ecco-jcc/jjy113 10.1136/gut.45.3.362 10.1002/ibd.20520 10.3390/molecules201019030 10.1111/apt.12335 |
ContentType | Journal Article |
Copyright | 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology 2020 |
Copyright_xml | – notice: 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology 2020 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.14309/ctg.0000000000000134 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection (Proquest) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2155-384X |
EndPage | e00134 |
ExternalDocumentID | 10_14309_ctg_0000000000000134 32352717 |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 8FI 8FJ AAAAV AAHPQ AAIQE AAKDD AASCR ABASU ABDIG ABUWG ABVCZ ACGFS ACILI ACSMW ACXJB ADBBV ADGGA ADHPY ADPDF ADRAZ AENEX AFDTB AFKRA AHMBA AHQNM AHVBC AINUH AJIOK AJNWD AJTQC AJZMW ALIPV ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOIJS BAWUL BCNDV BENPR BPHCQ BQLVK BVXVI C6C CAG CCPQU CGR COF CUY CVF DIK DIWNM EBS ECM EEVPB EIF EJD EMOBN FCALG FRP FYUFA GNXGY GQDEL GROUPED_DOAJ GX1 HLJTE HMCUK HYE HZ~ IKREB KQ8 M48 M~E NPM O9- OK1 OPUJH OVD OVDNE OVEED OXXIT PIMPY PQQKQ PROAC RLZ RNS RNT RNTTT RPM TEORI TSPGW UKHRP W2D AAYXX CITATION 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c439t-9266f344e7e607f6350ff12bf51512c393f8dfa3badb27ccb5c53f637d8289353 |
IEDL.DBID | RPM |
ISSN | 2155-384X |
IngestDate | Tue Sep 17 21:25:43 EDT 2024 Fri Aug 16 07:13:03 EDT 2024 Thu Oct 10 20:25:25 EDT 2024 Fri Aug 23 02:57:01 EDT 2024 Wed Oct 16 00:42:41 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c439t-9266f344e7e607f6350ff12bf51512c393f8dfa3badb27ccb5c53f637d8289353 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145033/ |
PMID | 32352717 |
PQID | 2459428506 |
PQPubID | 2041958 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7145033 proquest_miscellaneous_2397657542 proquest_journals_2459428506 crossref_primary_10_14309_ctg_0000000000000134 pubmed_primary_32352717 |
PublicationCentury | 2000 |
PublicationDate | 2020-03-01 |
PublicationDateYYYYMMDD | 2020-03-01 |
PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York – name: Philadelphia, PA |
PublicationTitle | Clinical and translational gastroenterology |
PublicationTitleAlternate | Clin Transl Gastroenterol |
PublicationYear | 2020 |
Publisher | Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins Wolters Kluwer |
Publisher_xml | – name: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins – name: Wolters Kluwer |
References | Sandborn (R20-20231031) 2014; 12 Sturm (R55-20231031) 2019; 13 Cui (R74-20231031) 2019; 10 Theede (R40-20231031) 2015; 13 Schroeder (R23-20231031) 1987; 317 Kristensen (R68-20231031) 2016; 51 Henriksen (R13-20231031) 2008; 57 Balzano (R64-20231031) 2015; 20 Colombel (R4-20231031) 2011; 141 Lopez (R44-20231031) 2017; 32 Zhao (R70-20231031) 2017; 36 Moran-Moguel (R53-20231031) 2018; 2018 Veltman (R16-20231031) 2012; 44 Berrill (R11-20231031) 2013; 38 Franks (R30-20231031) 2011; 8 Rogler (R32-20231031) 2015; 17 Antolín (R73-20231031) 2015; 15 Rutter (R63-20231031) 2004; 126 Khanna (R5-20231031) 2015; 386 Schaffer (R31-20231031) 2014; 8 Khanna (R29-20231031) 2014; 11 Cheng (R75-20231031) 2013; 8 Lewis (R18-20231031) 2008; 14 Rutgeerts (R22-20231031) 2005; 353 Baert (R3-20231031) 2010; 138 Peyrin-Biroulet (R25-20231031) 2016; 14 Lin (R43-20231031) 2014; 20 Sipponen (R57-20231031) 2008; 28 Kawaguchi (R71-20231031) 2013; 108 Sartor (R1-20231031) 2006; 3 Magro (R61-20231031) 2017; 11 Debast (R26-20231031) 2014; 20 Maaser (R54-20231031) 2019; 13 Best (R19-20231031) 1976; 70 Gracie (R12-20231031) 2016; 111 Solem (R14-20231031) 2005; 11 Fagan (R33-20231031) 1982; 12 McDonald (R76-20231031) 2011; 57 Kalla (R15-20231031) 2015; 64 af Björkesten (R36-20231031) 2012; 47 Mao (R41-20231031) 2012; 18 Meiri (R69-20231031) 2012; 17 D'Haens (R42-20231031) 2012; 18 Vavricka (R49-20231031) 2018; 6 Sipponen (R58-20231031) 2015; 50 Frøslie (R62-20231031) 2007; 133 Cordes (R17-20231031) 2016; 22 Lasson (R67-20231031) 2015; 9 Sýkora (R45-20231031) 2010; 99 Shah (R6-20231031) 2016; 14 Fang (R51-20231031) 2015; 34 Jopling (R77-20231031) 2012; 9 Chang (R56-20231031) 2018; 12 Arora (R9-20231031) 2009; 69 Labaere (R66-20231031) 2014; 2 Tibble (R47-20231031) 1999; 45 Shastri (R48-20231031) 2008; 121 Zanutto (R72-20231031) 2014; 110 Mooiweer (R59-20231031) 2015; 9 Hur (R52-20231031) 2015; 107 Annese (R28-20231031) 2013; 7 Koulaouzidis (R60-20231031) 2016; 61 Schoepfer (R35-20231031) 2010; 105 Baars (R10-20231031) 2012; 18 Chen (R38-20231031) 2017; 23 Titze-de-Almeida (R78-20231031) 2017; 34 Peyrin-Biroulet (R27-20231031) 2015; 110 Brookes (R39-20231031) 2018; 9 Daperno (R24-20231031) 2004; 60 Solberg (R2-20231031) 2007; 5 Colombel (R7-20231031) 2018; 390 D'Haens (R21-20231031) 2007; 132 Lüning (R8-20231031) 2007; 21 Vermeire (R37-20231031) 2006; 55 Schoepfer (R34-20231031) 2008; 14 Ertekin (R46-20231031) 2010; 44 von Roon (R50-20231031) 2007; 102 Whitehead (R65-20231031) 2013; 50 |
References_xml | – volume: 107 year: 2015 ident: R52-20231031 article-title: Identification of a metastasis-specific MicroRNA signature in human colorectal cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dju492 contributor: fullname: Hur – volume: 21 start-page: 994 year: 2007 ident: R8-20231031 article-title: Colonoscopic perforations: A review of 30,366 patients publication-title: Surg Endosc doi: 10.1007/s00464-007-9251-7 contributor: fullname: Lüning – volume: 34 start-page: 1339 year: 2017 ident: R78-20231031 article-title: The race of 10 synthetic RNAi-based drugs to the pharmaceutical market publication-title: Pharm Res doi: 10.1007/s11095-017-2134-2 contributor: fullname: Titze-de-Almeida – volume: 50 start-page: 74 year: 2015 ident: R58-20231031 article-title: Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease publication-title: Scand J Gastroenterol doi: 10.3109/00365521.2014.987809 contributor: fullname: Sipponen – volume: 11 start-page: 435 year: 2017 ident: R61-20231031 article-title: Accuracy of faecal calprotectin and Neutrophil gelatinase B-associated lipocalin in evaluating subclinical inflammation in UlceRaTIVE colitis-the ACERTIVE study publication-title: J Crohn's colitis contributor: fullname: Magro – volume: 105 start-page: 162 year: 2010 ident: R35-20231031 article-title: Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI publication-title: Am J Gastroenterol doi: 10.1038/ajg.2009.545 contributor: fullname: Schoepfer – volume: 18 start-page: 2218 year: 2012 ident: R42-20231031 article-title: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.22917 contributor: fullname: D'Haens – volume: 11 start-page: 707 year: 2005 ident: R14-20231031 article-title: Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000173271.18319.53 contributor: fullname: Solem – volume: 22 start-page: 2341 year: 2016 ident: R17-20231031 article-title: MicroRNA-320a strengthens intestinal barrier function and follows the course of experimental colitis publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000917 contributor: fullname: Cordes – volume: 34 start-page: 86 year: 2015 ident: R51-20231031 article-title: Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-015-0198-6 contributor: fullname: Fang – volume: 36 start-page: 77 year: 2017 ident: R70-20231031 article-title: Circulating microRNAs: Promising biomarkers involved in several cancers and other diseases publication-title: DNA Cel Biol doi: 10.1089/dna.2016.3426 contributor: fullname: Zhao – volume: 3 start-page: 390 year: 2006 ident: R1-20231031 article-title: Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis publication-title: Nat Clin Prac Gastroenterol Hepatol doi: 10.1038/ncpgasthep0528 contributor: fullname: Sartor – volume: 64 start-page: 504 year: 2015 ident: R15-20231031 article-title: MicroRNAs: New players in IBD publication-title: Gut doi: 10.1136/gutjnl-2014-307891 contributor: fullname: Kalla – volume: 353 start-page: 2462 year: 2005 ident: R22-20231031 article-title: Infliximab for induction and maintenance therapy for ulcerative colitis publication-title: N Engl J Med doi: 10.1056/NEJMoa050516 contributor: fullname: Rutgeerts – volume: 9 start-page: 50 year: 2015 ident: R59-20231031 article-title: Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: A plea for deep remission publication-title: J Crohn's colitis doi: 10.1093/ecco-jcc/jju003 contributor: fullname: Mooiweer – volume: 8 start-page: e64795 year: 2013 ident: R75-20231031 article-title: Plasma processing conditions substantially influence circulating microRNA biomarker levels publication-title: PLoS One doi: 10.1371/journal.pone.0064795 contributor: fullname: Cheng – volume: 17 start-page: 26 year: 2015 ident: R32-20231031 article-title: Clinical utility of biomarkers in IBD publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-015-0449-x contributor: fullname: Rogler – volume: 18 start-page: 1894 year: 2012 ident: R41-20231031 article-title: Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.22861 contributor: fullname: Mao – volume: 57 start-page: 1518 year: 2008 ident: R13-20231031 article-title: C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study publication-title: Gut doi: 10.1136/gut.2007.146357 contributor: fullname: Henriksen – volume: 5 start-page: 1430 year: 2007 ident: R2-20231031 article-title: Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2007.09.002 contributor: fullname: Solberg – volume: 138 start-page: 463 year: 2010 ident: R3-20231031 article-title: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.09.056 contributor: fullname: Baert – volume: 60 start-page: 505 year: 2004 ident: R24-20231031 article-title: Development and validation of a new, simplified endoscopic activity score for crohn's disease: The SES-CD publication-title: Gastrointest Endosc doi: 10.1016/S0016-5107(04)01878-4 contributor: fullname: Daperno – volume: 14 start-page: 1245 year: 2016 ident: R6-20231031 article-title: Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: A systematic review and meta-analysis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2016.01.015 contributor: fullname: Shah – volume: 14 start-page: 348 year: 2016 ident: R25-20231031 article-title: Defining disease severity in inflammatory bowel diseases: Current and future directions publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.06.001 contributor: fullname: Peyrin-Biroulet – volume: 17 start-page: 801 year: 2012 ident: R69-20231031 article-title: A second-generation microRNA-based assay for diagnosing tumor tissue origin publication-title: Oncologist doi: 10.1634/theoncologist.2011-0466 contributor: fullname: Meiri – volume: 15 start-page: 297 year: 2015 ident: R73-20231031 article-title: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer publication-title: BMC Cancer doi: 10.1186/s12885-015-1238-5 contributor: fullname: Antolín – volume: 6 start-page: 1007 year: 2018 ident: R49-20231031 article-title: The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding publication-title: United Eur Gastroenterol J doi: 10.1177/2050640618774416 contributor: fullname: Vavricka – volume: 69 start-page: 654 year: 2009 ident: R9-20231031 article-title: Risk of perforation from a colonoscopy in adults: A large population-based study publication-title: Gastrointest Endosc doi: 10.1016/j.gie.2008.09.008 contributor: fullname: Arora – volume: 13 start-page: 273 year: 2019 ident: R55-20231031 article-title: ECCO-ESGAR uideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects publication-title: J Crohn's colitis doi: 10.1093/ecco-jcc/jjy114 contributor: fullname: Sturm – volume: 2018 start-page: 2474529 year: 2018 ident: R53-20231031 article-title: Rheumatoid arthritis and miRNAs: A critical review through a functional view publication-title: J Immunol Res doi: 10.1155/2018/2474529 contributor: fullname: Moran-Moguel – volume: 32 start-page: 577 year: 2017 ident: R44-20231031 article-title: Fecal biomarkers in inflammatory bowel disease publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13611 contributor: fullname: Lopez – volume: 141 start-page: 1194 year: 2011 ident: R4-20231031 article-title: Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.06.054 contributor: fullname: Colombel – volume: 8 start-page: 359 year: 2011 ident: R30-20231031 article-title: IBD CRP is a good long-term biomarker publication-title: Nat Rev Gastroenterol Hepatol contributor: fullname: Franks – volume: 13 start-page: 1929 year: 2015 ident: R40-20231031 article-title: Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.05.038 contributor: fullname: Theede – volume: 12 start-page: 1485 year: 2014 ident: R20-20231031 article-title: A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.01.029 contributor: fullname: Sandborn – volume: 132 start-page: 763 year: 2007 ident: R21-20231031 article-title: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.12.038 contributor: fullname: D'Haens – volume: 133 start-page: 412 year: 2007 ident: R62-20231031 article-title: Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.05.051 contributor: fullname: Frøslie – volume: 390 start-page: 2779 year: 2018 ident: R7-20231031 article-title: Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32641-7 contributor: fullname: Colombel – volume: 110 start-page: 1324 year: 2015 ident: R27-20231031 article-title: Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target publication-title: Am J Gastroenterol doi: 10.1038/ajg.2015.233 contributor: fullname: Peyrin-Biroulet – volume: 23 start-page: 8235 year: 2017 ident: R38-20231031 article-title: Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China publication-title: World J Gastroenterol doi: 10.3748/wjg.v23.i46.8235 contributor: fullname: Chen – volume: 51 start-page: 548 year: 2016 ident: R68-20231031 article-title: Clinical importance of faecal calprotectin variability in inflammatory bowel disease: Intra-individual variability and standardisation of sampling procedure publication-title: Scand J Gastroenterol doi: 10.3109/00365521.2015.1117650 contributor: fullname: Kristensen – volume: 57 start-page: 833 year: 2011 ident: R76-20231031 article-title: Analysis of circulating microRNA: Preanalytical and analytical challenges publication-title: Clin Chem doi: 10.1373/clinchem.2010.157198 contributor: fullname: McDonald – volume: 99 start-page: 1389 year: 2010 ident: R45-20231031 article-title: Evaluation of faecal calprotectin as a valuable non-invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2010.01843.x contributor: fullname: Sýkora – volume: 9 start-page: 87 year: 2018 ident: R39-20231031 article-title: Practical guidance on the use of faecal calprotectin publication-title: Frontline Gastroenterol doi: 10.1136/flgastro-2016-100762 contributor: fullname: Brookes – volume: 8 start-page: 1125 year: 2014 ident: R31-20231031 article-title: Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2014.02.014 contributor: fullname: Schaffer – volume: 50 start-page: 53 year: 2013 ident: R65-20231031 article-title: Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits publication-title: Ann Clin Biochem doi: 10.1258/acb.2012.011272 contributor: fullname: Whitehead – volume: 121 start-page: 1099 year: 2008 ident: R48-20231031 article-title: Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea publication-title: Am J Med doi: 10.1016/j.amjmed.2008.06.034 contributor: fullname: Shastri – volume: 28 start-page: 1221 year: 2008 ident: R57-20231031 article-title: Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2008.03835.x contributor: fullname: Sipponen – volume: 102 start-page: 803 year: 2007 ident: R50-20231031 article-title: Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2007.01126.x contributor: fullname: von Roon – volume: 126 start-page: 451 year: 2004 ident: R63-20231031 article-title: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2003.11.010 contributor: fullname: Rutter – volume: 108 start-page: 361 year: 2013 ident: R71-20231031 article-title: Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer publication-title: Br J Cancer doi: 10.1038/bjc.2012.546 contributor: fullname: Kawaguchi – volume: 2 start-page: 30 year: 2014 ident: R66-20231031 article-title: Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease publication-title: United Eur Gastroenterol J doi: 10.1177/2050640613518201 contributor: fullname: Labaere – volume: 110 start-page: 1001 year: 2014 ident: R72-20231031 article-title: Circulating miR-378 in plasma: A reliable, haemolysis-independent biomarker for colorectal cancer publication-title: Br J Cancer doi: 10.1038/bjc.2013.819 contributor: fullname: Zanutto – volume: 70 start-page: 439 year: 1976 ident: R19-20231031 article-title: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study publication-title: Gastroenterology doi: 10.1016/S0016-5085(76)80163-1 contributor: fullname: Best – volume: 12 start-page: 117 year: 2018 ident: R56-20231031 article-title: Fecal immunochemical test and fecal calprotectin measurement are noninvasive monitoring tools for predicting endoscopic activity in patients with ulcerative colitis publication-title: Gut Liver doi: 10.5009/gnl17445 contributor: fullname: Chang – volume: 44 start-page: 341 year: 2012 ident: R16-20231031 article-title: Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2011.11.006 contributor: fullname: Veltman – volume: 9 start-page: 137 year: 2012 ident: R77-20231031 article-title: Liver-specific microRNA-122: Biogenesis and function publication-title: RNA Biol doi: 10.4161/rna.18827 contributor: fullname: Jopling – volume: 61 start-page: 2033 year: 2016 ident: R60-20231031 article-title: Association between fecal calprotectin levels and small-bowel inflammation score in capsule endoscopy: A multicenter retrospective study publication-title: Dig Dis Sci doi: 10.1007/s10620-016-4104-7 contributor: fullname: Koulaouzidis – volume: 317 start-page: 1625 year: 1987 ident: R23-20231031 article-title: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study publication-title: New Engl J Med doi: 10.1056/NEJM198712243172603 contributor: fullname: Schroeder – volume: 44 start-page: 544 year: 2010 ident: R46-20231031 article-title: Fecal calprotectin concentration in celiac disease publication-title: J Clin Gastroenterol doi: 10.1097/MCG.0b013e3181cadbc0 contributor: fullname: Ertekin – volume: 20 start-page: 1407 year: 2014 ident: R43-20231031 article-title: Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000057 contributor: fullname: Lin – volume: 18 start-page: 1634 year: 2012 ident: R10-20231031 article-title: Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.21925 contributor: fullname: Baars – volume: 10 start-page: 626 year: 2019 ident: R74-20231031 article-title: Circulating MicroRNAs in cancer: Potential and challenge publication-title: Front Genet doi: 10.3389/fgene.2019.00626 contributor: fullname: Cui – volume: 7 start-page: 982 year: 2013 ident: R28-20231031 article-title: European evidence based consensus for endoscopy in inflammatory bowel disease publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2013.09.016 contributor: fullname: Annese – volume: 47 start-page: 528 year: 2012 ident: R36-20231031 article-title: Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease publication-title: Scand J Gastroenterol doi: 10.3109/00365521.2012.660542 contributor: fullname: af Björkesten – volume: 55 start-page: 426 year: 2006 ident: R37-20231031 article-title: Laboratory markers in IBD: Useful, magic, or unnecessary toys? publication-title: Gut doi: 10.1136/gut.2005.069476 contributor: fullname: Vermeire – volume: 12 start-page: 351 year: 1982 ident: R33-20231031 article-title: Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis publication-title: Eur J Clin Invest doi: 10.1111/j.1365-2362.1982.tb02244.x contributor: fullname: Fagan – volume: 111 start-page: 541 year: 2016 ident: R12-20231031 article-title: Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease publication-title: Am J Gastroenterol doi: 10.1038/ajg.2016.59 contributor: fullname: Gracie – volume: 11 start-page: 9 year: 2014 ident: R29-20231031 article-title: IBD: Measuring what counts--endoscopic assessment in IBD publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2013.233 contributor: fullname: Khanna – volume: 20 start-page: 1 issue: Suppl 2 year: 2014 ident: R26-20231031 article-title: European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12418 contributor: fullname: Debast – volume: 14 start-page: 32 year: 2008 ident: R34-20231031 article-title: Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20275 contributor: fullname: Schoepfer – volume: 386 start-page: 1825 year: 2015 ident: R5-20231031 article-title: Early combined immunosuppression for the management of Crohn's disease (REACT): A cluster randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)00068-9 contributor: fullname: Khanna – volume: 9 start-page: 26 year: 2015 ident: R67-20231031 article-title: The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis publication-title: J Crohn's colitis contributor: fullname: Lasson – volume: 13 start-page: 144 year: 2019 ident: R54-20231031 article-title: ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications publication-title: J Crohn's colitis doi: 10.1093/ecco-jcc/jjy113 contributor: fullname: Maaser – volume: 45 start-page: 362 year: 1999 ident: R47-20231031 article-title: High prevalence of NSAID enteropathy as shown by a simple faecal test publication-title: Gut doi: 10.1136/gut.45.3.362 contributor: fullname: Tibble – volume: 14 start-page: 1660 year: 2008 ident: R18-20231031 article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20520 contributor: fullname: Lewis – volume: 20 start-page: 19030 year: 2015 ident: R64-20231031 article-title: miRNA stability in frozen plasma samples publication-title: Molecules doi: 10.3390/molecules201019030 contributor: fullname: Balzano – volume: 38 start-page: 44 year: 2013 ident: R11-20231031 article-title: Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: Examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12335 contributor: fullname: Berrill |
SSID | ssj0000402899 |
Score | 2.3348188 |
Snippet | In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers... OBJECTIVES: In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive... OBJECTIVES:In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive... OBJECTIVESIn patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | e00134 |
SubjectTerms | Adolescent Adult Biomarkers Biomarkers - blood Case-Control Studies Colitis, Ischemic - blood Colitis, Ischemic - diagnosis Colitis, Ischemic - microbiology Colitis, Ulcerative - blood Colitis, Ulcerative - diagnosis Colitis, Ulcerative - immunology Colitis, Ulcerative - pathology Colon - diagnostic imaging Colon - immunology Colon - pathology Colonoscopy Crohn Disease - blood Crohn Disease - diagnosis Crohn Disease - immunology Crohn Disease - pathology Crohns disease Diagnosis, Differential Enterocolitis, Pseudomembranous - blood Enterocolitis, Pseudomembranous - diagnosis Enterocolitis, Pseudomembranous - microbiology Female Healthy Volunteers Humans Inflammation Inflammatory bowel disease Intestinal Mucosa - diagnostic imaging Intestinal Mucosa - immunology Intestinal Mucosa - pathology Male Medical diagnosis MicroRNAs MicroRNAs - blood Middle Aged Pathophysiology Severity of Illness Index Young Adult |
SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgSIgL4k15KUhcC22TLOsJjZcQ0iaEQHCiatOE7UAHrBN_H7vNCgOJXuOole3Enx-1AY5yamjSiZWvg1Sjg5LnfkyVOR2TWx5qq21V8t_rt68fxM2TfHIBt7Erq5zeidVFnY80xchPIiFjhMoyaJ--vfs0NYqyq26ExjwsRKGgNO3C2WX_9q6JsqCKkkfhft0RPIhPdPlSNy2cPiEXs0bpD9L8XTD5wwJdrcCyg46sW8t6FeZMsQaLPZccX4fnHhXX3fW7Po-ClNWn9WPMKOiHB5n2XtTpGNbV9dAINizYbd1Zdcweh-UAiS3qyGuVe2dno0_TbNqAh6vL-_Nr341P8DWijNKP0fZaLoRRph0oi8gisDaMMivJymsec9vJbcqzNM8ipXUmteRIpnLywrjkm9AqRoXZBpYiDJEILU0ntSKweFkr9LNUGIWmLbNMeXA85V_yVnfJSMi7IIYnyPDkN8M92JtyOXGHZpx8i9iDw2YZ1Z1yGGlhRhOkIfwkaWyvB1u1UJo38gjRJLqnHqgZcTUE1Ep7dqUYDqqW2ioUlM_d-f-zdmEpIne7KkHbg1b5MTH7iEnK7MAp3hdVsOCH priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ZS8QwEB48QHwRb-tFBF-rbZNstg8i64UIKyIu-mRp08Rd0K7uVtR_70yPxfUA-5oJhclM5vs60xmA3ZQamjRD5Wov1khQ0tQNqTKnaVLLfW21LUr-25eN8464uJN3E1A3VKgUOPyV2tE8qc7gce_95eMQHf6AHF5wL9zX-UPZh7B-fC4mYToQXJDRtyvEX1zOglJrYfUvz5-7x6PUD-j5vYLyS0g6m4e5CkuyVnn4CzBhskWYaVfZ8iW4b1O13fVly-WBF7PSfQdDRl8B0bNp70mZn2EtXU6RYL2MXZWtVofstpd3Udii0TwVyXh21H8zo03L0Dk7vTk-d6t5Cq5G2JG7IQZjy4UwyjQ8ZRFqeNb6QWIlhX3NQ26bqY15EqdJoLROpJYcxVRKtIxLvgJTWT8za8BixCUSsaZpxlZ4Fm9vhcRL-YFvGjJJlAN7tf6i57JtRkR0gxQeocKj7wp3YLPWclQbQRQIGSI9kl7DgZ3RMto_JTXizPRfUYYAlaQ5vg6slocyeiMPEF4iX3VAjR3XSIB6a4-vZL1u0WNb-YISvOv_eO8GzAZEwovCtE2YygevZguRSp5sF7b3CZQP5UQ priority: 102 providerName: Scholars Portal |
Title | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32352717 https://www.proquest.com/docview/2459428506 https://search.proquest.com/docview/2397657542 https://pubmed.ncbi.nlm.nih.gov/PMC7145033 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED7aFEZfRtttnfsjaLBXJ7YlRfZj2rWUgkMoK8vTjC1LS2BxSuOwf793sh3S7q1-8ItP2JxOuu98n-4AvpdU0CROlK-DXGOAUpZ-Qsyc2JSWh9pq6yj_6WR09yjuZ3K2B7I7C-NI-7pYDKq_y0G1mDtu5dNSDzue2HCaXqtQUPZtuA_7ivOdEN1tv4KSZ0l7WkfwIBnq-k9Tp7C7Qk79eHiE6EO5VmU7Luk_nPmWLrnjf26P4GMLHNm4-cBj2DPVCXxI29T4J_idErXuYTL2eRTkrFmrz2tGv_xwGdPYH00yho110zKCLSo2beqqrtmvRT1HYYsWsnSZd3a1-me2gz7D4-3Nz-s7v22e4GvEGLWfoOe1XAijzChQFnFFYG0YFVaSj9c84TYubc6LvCwipXUhteQopkqKwbjkX6BXrSrzFViOIEQisDRxbkVgcatWGGWpMArNSBaF8mDQ6S97ampkZBRbkO4z1H32VvceXHRaztols84iIROMhWQw8uDb9jEaO2Uw8sqsNihD6ElS014PTptJ2b6xm00P1Kvp2gpQIe3XT9C-XEHt1p7O3j3yHA4jisMdN-0CevXzxlwiWKmLPproTPXh4OpmMn3ou5Af76mI-85sXwD_mexS |
link.rule.ids | 230,315,733,786,790,870,891,2236,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827,74100,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZT8MwDLY4JOAFcVPOIPFaaJtkWZ_QuDSOTQiB2BNVmyawBzpgRfx97LYrDCT6GketbCf-fNQG2E-poUkzVK72Yo0OSpq6IVXmNE1qua-ttkXJf6fbaN-Ly57sVQG3YVVWOboTi4s6HWiKkR8GQoYIlaXXOHp9c2lqFGVXqxEakzAtOBek56qn6hgLKij5E9WPO4J74aHOn8qWhaPH52LcJP3Bmb_LJX_Yn_MFmK-AI2uVkl6ECZMtwUynSo0vw2OHSutuuy2XB17MyrP6PmQU8sNjTHtPy2QMa-lyZATrZ-ym7Ks6ZA_9_BmJLWrIS5F5Z8eDT1NvWoH787O7k7ZbDU9wNWKM3A3R8louhFGm4SmLuMKz1g8SK8nGax5y20xtzJM4TQKldSK15EimUvLBuOSrMJUNMrMOLEYQIhFYmmZshWfxqlboZSk_8E1DJoly4GDEv-i17JERkW9BDI-Q4dFvhjuwNeJyVB2ZYfQtYAf26mVUdspgxJkZfCANoSdJQ3sdWCuFUr-RB4gl0Tl1QI2JqyagRtrjK1n_uWiorXxB2dyN_z9rF2bbd53r6Pqie7UJcwE53kUx2hZM5e8fZhvRSZ7sFCr4BTAn4g4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZ4SIgL4k15BolrWds0y3pC4zHx2oQQiJ2o2jSBHeiAFfH3sdusMJDoNYla2U78Of5qAxxkVNCkFUlXeYnCACXL3IiYOS2dGe4ro0xJ-e_2muf34WVf9C3_aWRpleMzsTyos6GiO_JGEIoIobLwmg1jaRE3p52j1zeXOkhRptW205iGWfSSHrVxkH1Z37egsVJsYX_iCbkXNVTxVJUvHD8-Dyfd0x_M-Zs6-cMXdRZhwYJI1q60vgRTOl-Gua5Nk6_AY5dodre9tssDL2HVvn0fMbr-wy1Na0-rxAxrq6p9BBvk7KaqsTpiD4PiGScbtJaXMgvPjoeful60Cveds7uTc9c2UnAV4o3CjdALGx6GWuqmJw1iDM8YP0iNIH-veMRNKzMJT5MsDaRSqVCC4zSZUTzGBV-DmXyY6w1gCQISgSBTtxITegaPbYkRl_QDXzdFmkoHDsfyi1-rehkxxRkk8BgFHv8WuAPbYynHdvuM4m9lO7BfD6PhUzYjyfXwA-cQkhLUwNeB9Uop9Rt5gLgSA1UH5IS66glUVHtyJB88l8W1pR9SZnfz_8_agzm0vvj6one1BfMBxeAlL20bZor3D72DQKVId0sL_AKpKeY6 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-320a+Monitors+Intestinal+Disease+Activity+in+Patients+With+Inflammatory+Bowel+Disease&rft.jtitle=Clinical+and+translational+gastroenterology&rft.au=Cordes%2C+Friederike&rft.au=Demmig%2C+Claudia&rft.au=Bokemeyer%2C+Arne&rft.au=Br%C3%BCckner%2C+Markus&rft.date=2020-03-01&rft.eissn=2155-384X&rft.volume=11&rft.issue=3&rft.spage=e00134&rft.epage=e00134&rft_id=info:doi/10.14309%2Fctg.0000000000000134&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2155-384X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2155-384X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2155-384X&client=summon |